Lonza has expanded its footprint for parenteral dosage form development by investing in its Drug Product Services (DPS) site, the company has announced.
Expansion
The expansion comes in response to market demand, with the company now increasing both the capability and capacity of DPS at its Stücki Science Park in Basel, Switzerland.
Lonza is also nearing the end of recruiting phase that will extend the number of DPS employees to 125 staff.
The expanded offering includes new capabilities for a range of services, including, clinical administration and compatibility testing; lyophilisation cycle and process development; device functionality testing and lifecycle management line extension.
Lonza DPS opened two years ago and has since developed solutions for 88 molecules. The site complements the company’s service in biologics with end-to-end capabilities.
Karen Fallen, senior vice president and head of clinical development and manufacturing, Lonza Pharma & Biotech, said: “Including drug product services in the portfolio provides our customers with a single supplier for their clinical outsourcing requirements. DPS customers recognise our commitment to their challenges. We have built an experienced team with the ability to solve problems based on scientific, industry and regulatory know-how.”